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Abstract
Endoscopic treatment of emphysema is supported by different
methods, including valves, coils and sealants. The mechanism is mainly
related to volume reduction of targeted area. Endobronchial valves
(EBV) appear the most studied method. In a multicentre randomised
study, placement of unidirectional endobronchial valves resulted in a
statistically significant functional improvement in the treated cohort
compared to the control. Adverse events, occurring post procedure, in-
cluded COPD exacerbations, haemoptysis, pneumothorax and pneu-
monia. In our centre we treated 30 patients, between January 2009 and
February 2012, with variable improvement of lung function and only
mild postoperative complications. The case we report here appears very
interesting for the unusual near-fatal complication (massive alveolar
haemorrage) followed by delayed strong functional improvement (FEV1
+23%; RV -18%; 6MWD:+33%) six months after the valve placement.
This improvement could be attributable to the EBV procedure, but an al-
ternative explanation is that the lung volume reduction may have been
enhanced by the complication itself, as an effect of alveolar collapse.
Case report
Endoscopic treatment of emphysema is supported by different
methods, including valves, coils and sealants [1-10]. The mechanism
is mainly related to volume reduction of targeted area. Endobronchial
valves (EBV) appear the most studied method. In a multicentre ran-
domised study, placement of unidirectional endobronchial valves re-
sulted in a statistically significant functional improvement in the
treated cohort compared to the control [4]. Adverse events occurring
post procedure included COPD exacerbations, haemoptysis, pneu-
mothorax and pneumonia. In our centre we treated 30 patients, be-
tween January 2009 and September 2012, with variable improvement
of lung function and only mild postoperative complications. The case
we report here appears very interesting for the dramatic and unusual
complication followed by delayed strong functional improvement. A 76
years old man with GOLD Stage IV emphysema and a BMI of 21 was
admitted for EBV placement having undergone a period of pulmonary
rehabilitation and optimisation of medical treatment according to our
hospital practice. He suffered from controlled arterial hypertension
and had an aortic valve replacement 12 years earlier at which time he
was diagnosed with emphysema and he stopped smoking. His medica-
tion included a long acting anticholinergic, beta-agonist, inhaled cor-
ticosteroids, theophylline, furosemide, candesartan and warfarin. Be-
fore the procedure, his FEV1 was 0.69 L (27% of predicted), RV 5.97L
(226% of predicted), 6MWT was 225 metres (53% of predicted), and
his MMRC Dyspnoea score was III. The BODE Index as proposed by B.
Celli et al. [11] at the time of admission was 8. Chest X-ray demon-
strated a significant flattening of the diaphragm with loss of lung
parenchyma bilaterally. CT scan demonstrated advanced heteroge-
neous emphysema, with basal bulla in the right lower lobe (Figures
1,2), and with the right lung appearing more hyperinflated than the
left; the fissure that separates the upper lobe from the other lobes ap-
peared visible and complete. A ventilation/perfusion scan demon-
strated a spotty bilateral distribution with reduced perfusion in the
right lung (46%) compared to the left lung. Platelet count was normal
on admission.
The patient was changed from warfarin to subcutaneous heparin on
admission. On the day of the procedure, heparin was discontinued and
clotting time and INR was within the normal range. The procedure was
performed in the endoscopy suite. The patient was sedated with opiates
and midazolam and was spontaneously breathing. A local anaesthetic
preparation was also administered. One large Zephyr Valve (Pulmonx,
Redwood City, CA) was placed by flexible bronchoscopy into the tar-
geted right upper lobe. Within 5 hours of the procedure, the patient be-
came tachypnoeic (respiratory rate >30/min), arterial blood gases rap-
idly deteriorated (PaO2 50 mmHg during oxygen delivered by reservoir,
PaCO2 70 mmHg, pH 7.20) and he began to complain mild hemoptysis.
Chest X-ray demonstrated the presence of a pneumothorax and >50%
loss of lung volume; a chest drain was immediately placed but his res-
piratory condition progressively worsened and the patient was trans-
ferred to the sub-intensive area.
A repeat chest X-ray revealed the lung re-expansion and a concomi-
tant 2 large parenchymal opacifications in the same lung. A CT scan
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two days after procedure showed a 6 cm collection of liquid mixed with
air in the bulla of the right lower lobe with a diffuse alveolar opacifica-
tion of the entire lower lobe (Figure 3), and a further collection of
dense fluid in the apical segment of the right lower lobe. A diagnosis of
intra-parenchymal and intra-fissure haemorrhage was considered.
pimeEDITRICE
Table 1. Data are presented as absolute value and as percent of predicted.
Variables FEV1 FVC FEV1/VC RV% TLC% DLCO PaO2 PaCO2 Pimax 6MWD
Preoperative data 0.69 L 3.25 L 20% 5.94 L 9.36 L 5.8 64 40 68% 225 mt
(27%) (96%) (226%) (147%) ml/mmHg/m mmHg mmHg (53%)
(25%)
50 days after procedure 0.70 L 1.44 L 49% 57 52
(27%) (42%) mmHg mmHg
6 months after procedure 0.85 L 3.22 L 26% 4.86 L 8.47 L 8.1 62 41 78% 300 mt
(34%) (96%) (184%) (134%) (35%) mmHg mmHg (71%)
Figure 1. CT scan before treatment.
Figure 2. CT scan before treatment.
Figure 3. CT scan 2 days after procedure.
Non-invasive ventilation (NIV) was commenced. His respiratory con-
dition remained critical, with persistent hypoxemia (PaO2 around 60
mmHg) and hypercapnia (PaCO2 >60 mmHg) under ventilation. He
remained haemodynamically stable. A bedside bronchoscopy 48 hours
after procedure revealed diffuse haemorrhage in the bronchial tree,
mainly in the lower lobe, with moderate bleeding from the right upper
lobe, where the valve appeared to operate well. Angiography of the
bronchial artery was performed and confirmed bleeding from the right
bronchial branch. Selective catheterisation of the superior bronchial
artery of the right lung was performed followed by the release of mi-
crospheres (Embozene® 700 micron) and by the insertion of one metal
coil in order to stop the bleeding.
Subsequently, his respiratory condition remained stable but he de-
veloped signs of right heart failure and a transient dysarthria but no
other neurological signs. The respiratory condition and general status
of the patient progressively improved (Table 1) and 50 days after the
valve placement the patient was discharged to a rehabilitation centre.
The patient was re-evaluated six months after the procedure. A CT
scan at that time demonstrated a partial atelectasis of right upper lobe
(Figure 4) and the reduction of the opacification of the right lower lobe
bulla while the alveolar compartment appeared cleared. Pulmonary
function tests, compared to preoperative values, were significantly im-
proved, confirming the right indication for endoscopic bronchial valve
treatment. FEV1 increased by 23% to 0.85 L, RV reduced by 18% to 4.86L
and his 6MWT increased by 33% to 300m (Table 1). BODE index im-
proved from 8 to 6.
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Discussions and conclusions
In a randomised study of endobronchial valves for advanced emphy-
sema [4], valve placement resulted in a modest but clinically signifi-
cant benefit but a larger benefit was observed in a subset of patients
with heterogeneous emphysema and complete fissures. In the high
heterogeneity sub-group, mean improvement FEV1 at 6 months was
10,7% and 6MWT was 12,4%; in the complete fissure subgroup FEV1
improvement was 16,2% and 6MWD 7,7%. COPD exacerbations,
haemoptysis, pneumothorax and pneumonia occurred more commonly
in the treatment group compared to the control group of standard med-
ical care in the first three months but were comparable during the pe-
riod from three to twelve months [4]. In our centre we treated 30 pa-
tients using unidirectional bronchial valves (Zephyr EBV (Pulmonx;
Redwood City, CA) with modest improvement of lung function (mean
FEV +7%; mean RV -8%; 6MWD +6%) and mild postoperative compli-
cations (pneumothorax in 2, haemoptysis in 1 and acute exacerbation
of COPD in 1); results and complications being similar to the complete
cohort analysis reported by Sciurba FC et al. [4]. The present case re-
ports a very unusual and dramatic complication after valve placement,
not only due to pneumothorax but also due to massive and diffuse
bleeding in the fissure and inside the bulla, as well as in the alveolar
compartment. The previous anticoagulation therapy could be consid-
ered a risk factor although the clotting time was in normal range at the
time of the procedure. The presence of a basal bulla in the right lower
lobe adjacent to the treated lobe may have increased the risk of the de-
velopment of a pneumothorax post procedure. A possible explanation of
the dramatic haemorrhage could be the rapid re-expansion of the lung
after chest drainage, similarly to a pulmonary oedema observed after
the expansion of the lung. Despite this complication, this patient ob-
tained a substantial clinical improvement with an increase in FEV1 of
23%, reduction in RV of 18% and improvement in 6MWT of 33% at six
months post procedure. In addition to the therapeutic effect from valve
therapy, it is possible that the intraparenchymal haemorrhage provided
a biological lung volume reduction mechanism whereby the haemor-
rhage induced an inflammatory reaction resulting in alveolar collapse.
However, it should be noted that the distribution of the blood was not
localised to the target lobe.
In conclusion, this patient experienced an unusual complication
with massive bleeding following EBV therapy. However, this patient
subsequently obtained a very good functional improvement, which
could be attributable to the EBV procedure, but an alternative explana-
tion is that the lung volume reduction may have been enhanced by the
complication itself. This case also supports the view that an early and
dramatic complication such as severe pulmonary hemorrhage does not
preclude the success of procedure.
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Figure 4. CT scan 6 months after procedure.
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